ArticleClinical and translational radiation oncology2026
Spatially fractionated radiotherapy for re-irradiation: feasibility, safety, treatment planning, and outcomes.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Surviving Cancer, Lacking Support: The Hidden Burden of Modern Radiation Oncology in the Treatment of Oligometastatic Disease.Cancers · 2026Review
- Implementation of VMAT-based lattice spatially fractionated radiation therapy (SFRT) across linac platforms: Practical considerations for QA and motion management.Journal of applied clinical medical physics · 2026Article
- Spatially fractionated radiation therapy (SFRT): a scoping review of dosimetric and biological evidence supporting a valley dose-driven translational framework.Radiation oncology (London, England) · 2026Article
- Review
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
- Respiratory motion effects and plan robustness for lattice radiation therapy.Frontiers in oncology · 2026Article
- Spatially fractionated radiation therapy for treating recurrent glioblastoma: a dosimetric feasibility study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatially fractionated radiotherapy (SFRT) is emerging as an option to deliver high dose radiation to bulky disease sites with an improved therapeutic ratio compared to established radiotherapy techniques. SFRT has not been previously studied for re-irradiation. We describe three patients with previously irradiated bulky oligometastatic disease to different sites (lung, thigh, and adrenal gland) who were re-treated with SFRT, with intention to relieve or prevent worsening of symptoms. Dose prescription was 66.7 Gy in 5 fractions to uniformly spaced lattice vertices in the gross tumour volume (GTV), with the planning target volume (PTV) receiving 20 Gy at the periphery and a mean dose of approximately 27 Gy. Dose summation and image registration techniques, and selection of organs at risk and dose constraints, were defined on a case-by-case basis. GTV volumes ranged from 272 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.